FDA- HFpEF-breakthrough-designation-EMPEROR-preserved

Empagliflozin receives Breakthrough Therapy Designation in U.S. for heart failure with preserved ejection fraction (HFpEF)Breakthrough Designation awarded following empagliflozin ’s results in first and only successful trial for HFpEF
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news